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Abstract: Cystic echinococcosis (CE) remains an impor-
tant health problem in many regions of the world, both
where no control measures have been implemented, and
where control programs have been incompletely success-
ful with ensuing re-emergence of the disease. In Spain,
official data on CE show an increase in the proportion of
intermediate hosts with CE during the last few years, and
autochthonous pediatric patients have been reported, a
sign of active local transmission of disease. A similar
picture emerges from data reported to the European
Food Safety Authority by other European countries.
Nevertheless, several crucial aspects related to CE that
would help better understand and control the disease
have not been tackled appropriately, in particular the
emergence of infection in specific geographical areas. In
this respect, while some data are missing, other data are
conflicting because they come from different databases.
We review the current situation of CE in Spain compared
with areas in which similar problems in the CE field exist,
and offer recommendations on how to overcome those
limitations. Specifically, we believe that the introduction
of national registries for CE with online data entry,
following the example set by the European Registry for
Alveolar Echinococcosis, would help streamline data
collection on CE by eliminating the need for evaluating
and integrating data from multiple regions, by avoiding
duplication of data from patients who access several
different health facilities over time, and by providing
much needed clinical and epidemiological data that are
currently accessible only to clinicians.
Introduction
Echinococcus granulosus is a cestode whose larval stage causes cystic
echinococcosis (CE) in livestock, wild animals, and humans. CE is
acquired by ingesting eggs, originating from the faeces of definitive
hosts (dogs, wolves, and other carnivores), that harbour the adult
E. granulosus worms in their small intestine (Figure 1). CE is a
neglected disease and the cause of significant losses in endemic
areas [1,2].
Where the importance of CE has been recognized, control
programs have been implemented, leading to a drastic reduction
in its prevalence. This has also caused the discontinuation of
control measures and the exclusion of CE from the list of notifiable
diseases.
Several publications have documented the re-emergence of CE
in different European areas, e.g., Wales [3] and Spain [4], where
high incidence rates of echinococcosis in dogs and new CE
autochthonous cases in young people have been recently reported.
As a result, CE has a renewed importance in Europe [5]. This has
also been recognized by the European authorities through
directive 2003/99/EC, in which CE is a disease to be reported
to the European Food Safety Authority (EFSA).
This re-emergence should raise our awareness of crucial and
incompletely elucidated aspects of this disease. Here, we present
the latest data about CE in Spain and the suggestions from an
expert panel about issues that have not been addressed, with a look
at other countries that share the problem.
Methods
We ran a Medline search using ‘‘cystic echinococcosis’’ and
‘‘hydatid’’ combined with ‘‘epidemiology’’, ‘‘diagnosis’’, and
‘‘control programs’’ as keywords. Additional articles were obtained
from non-SCI journals published in Spain, Portugal, Italy, etc.
Individual articles and other pieces of information were not
excluded with regard to potential biases, since one of the goals was
also to discuss said biases.
Statistics on CE in Spain and Europe were retrieved from the
Ministerio de Sanidad y Consumo (http://www.msps.es), the
Ministerio de Medio Ambiente y Medio Rural y Marino, Spain
(http://www.mapa.es), and the EFSA (http://www.efsa.europa.
eu). The review also drew on conference proceedings, original
research conducted by the authors, and discussions in specific
forums (e.g., the Conferences of the Spanish Hidatidology
Association held in 2008 and 2010 at Salamanca, Spain).
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Changes
The lack of reliable statistics on the epidemiology of echinococ-
cosis in dogs makes it difficult to compare prevalence rates before
and after the application of control programs in Spain. A similar
picture is found in other European countries, in which data about
dog infection rates are scarce and difficult to interpret. Monitoring
and notification of echinococcosis in dogs is not compulsory in
Europe, and this information is not available to the EFSA.
The most complete data published to date about Spain are
those from the CE control campaign in the northern Spanish
region of La Rioja [6]. This campaign started in 1986, and CE
prevalence in the definitive host, measured by necropsy of stray
and unwanted dogs, was 7% at the beginning of the program, and
0.2% in 2000. A later study performed on shepherd dogs using E.
granulosus coproantigen detection in the region of Alava, close to La
Rioja, showed 8% of dogs to be positive [7]. Coproantigen ELISA
tests to detect echinococcosis in definitive hosts are well established
and documented [8], meaning that an active transmission of the
parasite actually occurs in defined environments nowadays.
A similar situation following the discontinuation of respective
control programs can be found in other European regions, such as
Wales, where prevalence in rural dogs increased from 3.4% in
1989 to 8.1% in 2002 [3]. Although the information that can be
a
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Figure 1. Epidemiology of Echinococcus granulosus in Spain. The
main domestic cycle is maintained between dogs and sheep, with man
as accidental intermediate host (a; white arrows). Wild cycles could
occur between wolves, wild boars, and cervids, among others (b). The
sylvatic cycle could be occasionally peridomestic (black arrow), since
the G1 genotype, the most frequent in sheep and human patients, has
been found in isolates from wild animals.
doi:10.1371/journal.pntd.0000893.g001
Key Learning Points
N Cystic echinococcosis (CE) remains one of the main
zoonoses in both developing and developed countries,
due to its complex clinical presentation, and causes a
substantial number of cases in some areas.
N Recent analyses have shown that CE is a re-emerging
disease with a remarkable economic impact in devel-
oped countries such as Spain.
N In spite of numerous studies, evidence-based and
standardized/agreed approaches are still needed to
define appropriate strategies for the epidemiological
evaluation, immunodiagnosis, and clinical management
of CE, among other aspects.
N The need for a continuous, homogeneous, and well-
defined source of epidemiological data on human CE,
improving the current EFSA reports, and modeling
national registries after the European Registry for
Alveolar Echinococcosis, is emphasized.
Five Key Papers in the Field
1. Brunetti E, Kern P, Vuitton DA; Writing Panel for the
WHO-IWGE (2010) Expert consensus for the diagnosis
and treatment of cystic and alveolar echinococcosis in
humans. Acta Trop 114: 1–16.
2. Brunetti E, Junghanss T (2009) Update on cystic hydatid
disease. Curr Opin Infect Dis 22: 497–502.
3. Budke CM, Deplazes P, Torgerson PR (2006) Global
socioeconomic impact of cystic echinococcosis. Emerg
Infect Dis 12: 296–303.
4. Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, et al.
(2003) European echinococcosis registry: human alveolar
echinococcosis, Europe, 1982–2000. European Echino-
coccosis Registry. Emerg Infect Dis 9:343–349.
5. Craig PS, Budke CM, Schantz PM, Li T, Qiu JJ, et al. (2007)
Human echinococcosis: a neglected disease? Trop Med
Health 35: 283–292.
Recommendations
1. Notification of human CE and echinococcosis surveillance
should be compulsory at the national level in European
countries.
2. More detailed and uniform surveillance and confirmation
criteria of cases for CE and echinococccosis in animals
and human patients should be established in Europe.
3. Tools for the detection of CE applicable to epidemiolog-
ical, diagnostic, and follow-up purposes should be
standardized and widely agreed upon.
4. Genotyping of Echinococcus granulosus isolates from
human patients and from wild hosts should be carried
out for a proper assessment of the current epidemiolog-
ical situation in Europe.
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suggest that rural and semi-rural dog populations are still at risk of
infection with E. granulosus in these and in other regions of Europe
where similar control campaigns had taken place.
A second point of concern is the role of wild definitive hosts in
the epidemiology of E. granulosus. Infection with E. granulosus has
been recently reported in the Iberian wolf [9,10]. Although sample
sizes are small, these authors claim that prevalence of echinococ-
cosis in wolves, whose number increased in Europe in recent years
due to protection policies (http://ec.europa.eu/environment/
nature/conservation), might be higher than 14% in some regions
of Spain [10]. More importantly, all positive wolves harbored
gravid worms from the G1 strain [10], the cause of most human
infections (reviewed in [11]). Wolves parasitized with E. granulosus
have also been found in Belarus, Italy, Finland, and Bulgaria [12–
15], with prevalence rates from 11.5% to 36%. Wild definitive
hosts may contribute to the spread of human and animal CE in
domestic cycles (Figure 1), and their role deserves further study in
specific areas. Additional factors, such as the economic, social, and
cultural conditions, sheep rising in extensive or semi-extensive
(non-confined) systems, and transhumance may all facilitate the
cross-talk of wild cycles with domestic environments.
Moreover, the prevalence of CE in domestic animals reported
in recent studies on control campaigns differs from official data in
some countries. In Spain, a CE prevalence of 0.98% for ovine and
goats is officially recorded in 2000, while data recovered by
personnel working in CE control programs showed 20 times that
prevalence for sheep in specific Spanish regions, such as La Rioja,
for the same year [6]. Official data show that from 2000 to 2008
(Table 1), bovine CE has decreased from 0.97% in 2000 to around
0.5% in 2008. Swine CE has been slowly decreasing from 2000 to
2008, although this data refers to intensively raised animals only.
When data from extensively raised animals are available,
prevalence rates are much higher compared to those in intensive
(confined) farming animals. For example, in 2007 0.81% of
extensively raised pigs had CE, compared with 0.02% of pigs
maintained under intensive raising (Table 1). The higher
prevalence found in extensive farm systems compared with
intensively raised animals in pigs could also extend to other
extensively raised CE hosts, e.g., sheep, which hosts the G1
human-infective strain. Sheep and goat CE remained below 2%
from 2000 to 2007, but data from 2008 show that 3.68% of
slaughtered animals were infected. Potential biases affecting data
from 2008 and not affecting previous reports, e.g., the total
number of inspected animals, are excluded, since the EFSA
reports from 2007 and 2008 show that the number of inspected
sheep and goats in Spain was higher in 2007 than in 2008.
Similarly, other sources of error that might affect CE rates, such as
the average animal’s age, are excluded since no specific campaign
for the slaughtering of old animals—with a higher likelihood of
presenting visible cysts—had been carried out in Spain in that
period. CE levels above 2% in sheep have also been reported to
the EFSA in 2008 (http://www.efsa.europa.eu/en/scdocs/scdoc/
1496.htm) in Bulgaria (4.3%), Italy (11.3%), Poland (6.7%), and
Romania (5%). High levels of sheep CE were also reported in
Portugal and Greece in 2007 (9.4% and 3.9%, respectively;
http://www.efsa.europa.eu/en/scdocs/scdoc/223r.htm).
The potential role of wild intermediate hosts in the maintenance
and spreading of CE into domestic environments is of interest to
Spain. Data provided to the EFSA from Spain represent a
proportion of randomly inspected hunted animals for human
consumption. However, the detection of fertile cysts in wild boar
suggest that this species may be involved in the epidemiology of E.
granulosus, particularly considering that large amounts of carcass
are available to dogs and wolves during the hunting season. The
recent population increase of wild boar in Spain, and the DNA
analysis showing that they harbor the G1 strain, indicates the
importance of this wild host for public health in Spain [16] and in
other European countries [17]. Estimated prevalence rates of CE
in wild boars have only been reported in the last four national
reports in Spain (from 2005 to 2008), showing an increase from
0.04% to 0.17% (Table 1). Cervid CE in Spain has been evaluated
only from 2006, showing a low prevalence with a small increase in
the last reported year (Table 1). Although the role of cervids in
domestic-transmitted CE is probably minor due to the possible
restriction to European cervids of the E. granulosus G10 genotype
(reviewed in [18]), more detailed genotyping studies should be
conducted to rule out G10 human infection or cervid infections
with E. granulosus genotypes other than G10.
G7 may also play a role in human infections. It has been found
in pigs, goats, and humans in Austria, Yugoslavia, Romania,
Poland, Spain, and Turkey [19–21]. The importance of this and
other genotypes in the epidemiology of CE is not well known, so
molecular typing of human isolates of E. granulosus deserves to be
systematically carried out in several areas of Europe.
Current Situation of Human CE in Spain
In Spain, human CE has been a notifiable disease from 1982 to
1996. The Spanish official statistics showed a human CE incidence
of 2.52 cases per 100,000 inhabitants in 1982. Control programs
were started between 1986 and 1990 in different regions of the
country, and were mainly based on the periodic treatment of dogs
with praziquantel. This, and the strict control of carcasses after the
occurrence of animal diseases such as spongiform encephalopathy
in cattle and blue tongue in sheep, resulted in the decrease of
human CE incidence to 1.01/100,000 inhabitants in 1996
(reviewed in [22]). From 1996 onwards, human CE cases
registered at the national level have been those spontaneously
declared by the different regions to the state authorities, and this
may represent a problem, as stated by other authors from different
European countries [5,23]. In Spain, a comparison of notified
cases with data from hospital records has shown that human CE
case numbers have been clearly underestimated in the last 10 years
(e.g., [4]). Thus, and for specific regions of Spain e.g., Castilla-
Leo ´n, the declared CE cases were 2.69/100,000, while those
calculated from hospital records was four times higher for the same
period [4]. Similarly, the latest surgical CE rates in Greece,
Portugal, and Italy [23–26] were 12/100,000, 12.2/100,000, and
Table 1. Prevalence (%) of cystic echinococcosis in livestock
and wild animals in Spain from 2000 to 2008.
Animals Year
2000 2001 2002 2003 2004 2005 2006 2007 2008
Bovine 0.97 0.79 0.70 0.59 0.59 0.70 0.75 0.50 0.52
Swine (intensive) 0.20 0.04 0.03 0.03 0.07 0.03 0.05 0.02 0.03
Swine (extensive) NA NA NA NA NA NA 0.49 0.81 0.37
Sheep and goats 0.98 1.18 1.01 0.67 0.46 0.57 0.45 0.57 3.68
Wild boar NA NA NA NA NA 0.04 0.06 0.13 0.17
Cervids NA NA NA NA NA NA 0.01 0.01 0.05
Source: Ministerio de Medio Ambiente y Medio Rural y Marino, Spain. NA, not
available.
doi:10.1371/journal.pntd.0000893.t001
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notification of human CE to the EFSA from 2004 to 2008 from
the same countries has been approximately ten times lower.
In addition, an increase of autochthonous cases of human CE
was officially reported in 2006, with 0.54 cases per 100,000
inhabitants at the national level in Spain, this being the highest
rate in the last 7 years (Table 2). More importantly, several
pediatric cases were detected over that time period, indicating an
active transmission of the parasite [27] (Figure 2). Re-emergence
of human CE is also found in several countries where specific
control programs have been applied in the past (reviewed in
[1,28]). This means that risk factors associated with human
infection in different areas should be specifically assessed. In Spain,
these risk factors were enumerated before the cessation of
respective control campaigns by Campos-Bueno et al. [29]. Due
to potential changes in the epidemiology of the parasite
transmission, they should be re-evaluated in patients acquiring
the infection in the last ten to 15 years in defined areas, as
suggested by a study recently done in Germany [5]. Unfortunately,
this re-evaluation cannot be performed with the currently
available information from EFSA, since that does not include
traceability of human cases related with crucial aspects such as
occupational and other risks (e.g., hunting). The autochthonous
character of human cases, an important factor for decisions on
control measures, should in theory be assessed with the EFSA
data, but their reliability is weakened by the fact that some
countries, including Spain, have reported all cases from 2004 to
2008 as domestic. This is difficult to believe, since a sizeable
proportion (30%–60%, depending on the hospital) of CE cases
from Spanish hospital records correspond to immigrants from
endemic countries (M. Siles-Lucas, J. Pardo-Lledias, and A.
Hernandez-Gonzalez, unpublished data), as expected of a country
where immigrants are more than 10% of the general population.
A comparison of CE human cases presented in three different
Spanish databases, together with the cases notified to the EFSA
and those notified by authorities in a specific Spanish region
(Castilla-Leo ´n) for the period 2000–2008, is shown in Table 2.
Problems Peculiar to CE and Limitations of the
EFSA Reports: Relevance for the European
Endemic Zone
Short-term, periodic de-worming of dogs was one of the key
points of control programs in Spain, but as it has been
discontinued, deparasitation of dogs is now done once or twice a
year, thus not covering the much shorter prepatent period of E.
granulosus adult worms if present. This may result in the survival of
the parasite in specific dog populations that actively shed the
parasite. This seems to be the case in Spain, since animal CE has
re-emerged and human CE also involves pediatric patients, and
may well apply to other European countries with similar
epidemiological scenarios.
Although the infection in dogs is probably the first indication of
an active transmission of the parasite, data about infection rates in
this and other E. granulosus definitive hosts are not notifiable to the
EFSA. Interestingly, however, some data about fox infection with
Echinococcus multilocularis are detailed in the EFSA annual report.
Data about dog prevalences are only found in a few
publications, and are frequently biased since there is no consensus
Figure 2. Age distribution of cystic echinococcosis human cases reported in Spain in 2006. Source: National Statistics Institute. Five
autochthonous CE cases are found in the age range 5–14 years, indicating active transmission of the parasite. The rest of the cases are distributed as
follows: 11 cases among 15- to 24-year-old patients, 19 among those aged 25–34, 36 among those aged 35–44, 46 among those aged 45–54, 40
among those aged 55–64, 54 among those aged 65–74, 27 among those aged 75–84, and five among patients aged 85 years old or more.
doi:10.1371/journal.pntd.0000893.g002
Table 2. Reported cases per 100,000 inhabitants of cystic
echinococcosis in Spain from 2000 to 2008.
Source Year
2000 2001 2002 2003 2004 2005 2006 2007 2008
EDOs 0.45 0.45 0.48 0.43 0.39 0.37 0.54 0.40 0.40
EFSA NA NA NA NA ,0.01 0.20 0.20 0.30 0.20
SIM 0.10 0.02 0.08 0.06 0.02 ,0.01 0.00 0.06 0.03
CMBS 2.04 1.75 1.75 1.74 1.80 1.39 NA NA NA
Castilla-Leo ´n 1.62 1.70 2.84 2.11 2.00 1.88 2.97 1.90 NA
Source: Ministerio de Sanidad, Spain, from the databases ‘‘Enfermedades de
Declaracio ´n Obligatoria’’ (EDOs), ‘‘Sistema Microbiolo ´gico de Informacio ´n’’
(SIM), and ‘‘Conjunto Mı ´nimo Ba ´sico de Datos’’ (CMBS); European Food Security
Authority (EFSA); and Consejeria de Sanidad y Bienestar Social de la Junta de
Castilla y Leo ´n (Castilla-Leo ´n). NA, not available.
doi:10.1371/journal.pntd.0000893.t002
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age structure, number of samples, etc.) or on the diagnostic
method to use. In most studies, these variables are not or are only
partly considered; thus, interpretation of tendencies or of specific
time-point data is impossible. In any case, the results of studies on
prevalence in dogs from several European countries are worri-
some. Those done in Spain, and more specifically in Alava on
shepherd dogs using coproantigen detection [7], and data from
Wales [3] and some Italian regions (reviewed in [30]), show dogs
to be infected at a rate of about 10%.
Data from farm animal CE prevalence in Spain reported to the
EFSA are obtained on all slaughtered animals by inspection each
year. Even so, these are probably underestimations, as the vast
majority of slaughtered animals—especially sheep—are less than 1
year old, less than the time needed for the oncosphere to develop
into a visible lesion; only 4% of slaughtered sheep in 2008 in Spain
were older than 12 months (http://www.mapa.es/es/ganaderia).
An example of this underestimation can be found in the official
data from the Spanish Castilla-Leo ´n region, where reports on
sheep CE was 3.87% for animals under 12 months of age, and
38.47% for sheep older than 5 years (http://www.salud.jcyl.es/
sanidad/cm?locale=es_ES&textOnly=false). Here, the problem
is related to the animal’s age at the time of sacrifice, although data
are probably showing the true tendency of CE in Spain, since all
slaughtered animals are reported. Nevertheless, underestimations
have consequences on policy making, resulting in the minimiza-
tion of the true importance of the problem and in playing down
the need of new and better documented studies.
In other European countries, CE data on farm animals reported
to EFSA are limited to small numbers far inferior to the total of
slaughtered animals in the same period. For example, Italy reports
data of CE in sheep for 358,602 animals in 2008, while
FAOSTAT data shows that in 2008 6,189,767 sheep were
slaughtered in Italy (http://faostat.fao.org/site/603/default.as-
px#ancor). It is impossible to know whether the reported animals
were randomly selected from several areas or are from a specific
area inside the country in which CE incidence is high, medium, or
low, and this makes discerning trends, if any, impossible.
Important additional information to assess CE epidemiology
such as age, geographical origin, or raising practices for animals is
not collected. In our opinion, these data would be easily obtained
in countries where an animal tracking system has been imposed by
the authorities, like in Spain (http://www.mapa.es/es/ganaderia/
pags/rega/riiaremo.htm).
Data from CE in wild animals are reported to EFSA by some
European countries, representing, in the case of Spain, only a
proportion of randomly inspected hunted animals. We are not
aware of the mandatory character of inspections or of the
proportion of animals inspected in other European countries.
Unfortunately, the extent and significance of infection of wildlife for
humanscannotbeassessed with the currentlyavailabledata.A clear
protocol on how to collect information about CE rates in wild
animals, as well as typing of E. granulosus isolates, should be outlined.
Regarding human CE data, Spain has three different databases:
the ‘‘Enfermedades de Declaracio ´n Obligatoria’’ or EDOs
(declarable diseases), the ‘‘Sistema de Informacio ´n Microbiolo ´-
gica’’ (SIM, system of microbiological information), and the
‘‘Conjunto Mı ´nimo Ba ´sico de Datos’’ (CMBD, minimum
database). All are maintained by the Spanish Ministry of Health,
but each database gives a different number of human CE cases for
the same year (Table 2). The CMDB database shows the highest
CE rates, although it only reports CE patients who underwent
surgery. Nevertheless, a variable amount of cysts remain clinically
silent or are not surgically removed [31].
Furthermore, the EDOs data should be transferred to the
EFSA, but Spanish data of human CE in the EFSA reports also
differ from EDOs, SIM, and CMBD (Table 2). Differences
between EDOs and EFSA-declared data might be due to the
method used for case confirmation, which should be histopathol-
ogy. Thus, EFSA figures may represent only a fraction of EDOs.
Nevertheless, discrepancies between both databases are also
related with relative proportion of patients along time, since they
do not indicate the same trend over time.
Notification systems in other European countries may suffer
from the same problems. Additionally, in some European
countries such as Italy, the notification for human CE has also
ceased to be mandatory. The ensuing underreporting leads
authorities to think that CE is not an important health problem,
which in turn makes measurement of disease burden even more
difficult.
Human CE data in the EFSA reports are sometimes
accompanied by tables with age distribution of cases, showing
the occurrence of pediatric cases, but these are not assigned to a
specific country. Even if they were, a second problem would
remain, the autochthonous character of human cases, which has
epidemiological and policy making implications. Autochtonous
cases are reported for some countries in the EFSA bulletin, but as
mentioned above, Spain has declared all cases from 2004 to 2008
as domestic. These data are hardly credible for the reasons
mentioned above (M. Siles-Lucas, J. Pardo-Lledias, and A.
Hernandez-Gonzalez, unpublished).
To make matters worse, CE has many clinical peculiarities with
epidemiological implications. The understanding of the natural
history of liver cysts has greatly improved with the use of
ultrasound and of a standardized classification [32–34], but these
important details are not collected in the notification form.
Further, given the chronic nature of their illness and the frequent
relapses, patients with CE often move from one treatment center
to another, which also contributes to unreliable statistics. In any
case, traceability of human cases, as well as other aspects
important for the re-evaluation of the epidemiological situation
of CE in Europe, such as occupation and previous or current
residence in an endemic area, should be obtained.
Conclusions
Available information on CE is incomplete and is insufficient to
assess properly its epidemiology in Spain and other European
countries. CE importance tends to be underestimated due to
underreporting and to the lack of compulsory notification. In spite
of this, Benner et al. [35] attempted to calculate the overall
economic losses due to human and animal CE in Spain in 2005.
Assuming no underreporting, they estimated an annual loss of
J148,964,534. This shows the need for increased monitoring and
control of CE in those countries where CE continues to affect
certain areas despite several control initiatives. We believe that
these limitations could be overcome, at a relatively low cost, with
the establishment of national registries for CE with Internet
electronic data entry, following the example set by the European
Registry for Alveolar Echinococcosis [36]. The registry would help
streamline data collection on CE by eliminating the need for
evaluating and integrating separate data from multiple regions, by
avoiding duplication of data from patients who access several
different health facilities over time, and by providing much needed
clinical and epidemiological data that are currently accessible only
to single clinicians. The registry could be used as a tool to
prioritize control measures for what is essentially a preventable
disease. Unsurprisingly, these suggestions are similar to those
www.plosntds.org 5 January 2011 | Volume 5 | Issue 1 | e893offered by the Scientific Panel on Animal Health and Welfare in
Europe to the EFSA regarding E. multilocularis [37]. Indeed, the
problems outlined in this review regard not only CE, but other
neglected zoonotic diseases as well, such as cysticercosis.
CE warrants more attention from clinicians, but their
coordination with veterinarians and policy makers is also required
to implement a more effective approach to CE control.
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